“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
HOME > REGULATORY
REGULATORY
- First Generics for 5 APIs Join NHI Price List, Main Targets Are Nexium/Lexapro
December 9, 2022
- Panel OKs Moderna Boosters for Age 12 and Up
December 9, 2022
- Industry Prods Special Inflation Measure in Off Year, Payers Don’t See Much Need: Chuikyo Hearing
December 8, 2022
- Japan Offers Mpox Vaccines to Columbia for Free
December 8, 2022
- Man Sues PMDA over Rejected Relief Claim for “Ranitidine Caused Cancer”
December 7, 2022
- Lilly’s Insulin Lyumjev Gets Label Update for Pediatric Use
December 7, 2022
- Delete Contraindications on Use of Amlodipine, Nifedipine in Pregnant Women: MHLW
December 6, 2022
- Susmed’s Insomnia App Up for PAFSC Review on December 19
December 6, 2022
- PAFSC Committee OKs Plan to Monitor Early Safety Signals from Xocova Using MID-NET
December 5, 2022
- LDP Committee Underscores Critical Situation of Drugs in Off-Year Discussions
December 5, 2022
- NHI-Market Price Gap Narrowed, but Chuikyo Payer Reps Say Normal Revision Possible
December 5, 2022
- LDP Project Team Submits Proposal, Calls for Limiting Off-Year Coverage to Drugs with Larger-than-Average Price Gap
December 5, 2022
- Japan Enacts Bill to Amend Infectious Disease Act
December 5, 2022
- Japan Enacts FY2022 Extra Budget, Reserves Nearly 4 Trillion Yen for COVID Response, Medical DX, Childcare
December 5, 2022
- Industry Hews to “No” to Off-Year Plan, but Wants Special Steps If It Is to Happen: LDP Confab
December 2, 2022
- Finance Minister Says Wants to “Reduce People’s Burdens” via Drug Price Revision
December 2, 2022
- Average NHI-Market Price Gap for 2023 Off-Year Revision at 7.0%: MHLW
December 2, 2022
- Japan Plans to Lower Minimum Age for Moderna COVID Booster to 12
December 2, 2022
- Evusheld Shelf Life Extended for 6 Months in Japan
December 1, 2022
- MOF Panel Presses for Full Annual Price Cuts, Rethink of COVID-Related Government Purchase
November 30, 2022
ページ
Companies don’t plan to fail when it comes to recruitment, but many fail to plan. What happens if your marketing director resigns? A recruiting plan gives your organization the confidence in knowing that whatever happens, there is a process in…
Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…